75 results on '"Guzmán-Fulgencio M"'
Search Results
2. Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients
- Author
-
Guzmán-Fulgencio, M., Berenguer, J., Pineda-Tenor, D., Jiménez-Sousa, M. A., García-Álvarez, M., Aldámiz-Echevarria, T., Carrero, A., Diez, C., Tejerina, F., Vázquez, S., Briz, V., and Resino, S.
- Published
- 2015
- Full Text
- View/download PDF
3. Association of torque teno virus (TTV) and torque teno mini virus (TTMV) with liver disease among patients coinfected with human immunodeficiency virus and hepatitis C virus
- Author
-
García-Álvarez, M., Berenguer, J., Álvarez, E., Guzmán-Fulgencio, M., Cosín, J., Miralles, P., Catalán, P., López, J. C., Rodríguez, J. Ma, Micheloud, D., Muñoz-Fernández, Ma Á., and Resino, S.
- Published
- 2013
- Full Text
- View/download PDF
4. Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy
- Author
-
Guzmán-Fulgencio, M., Berenguer, J., García-Álvarez, M., Micheloud, D., C. López, J., Cosín, J., Fernández de Castro, I., Catalán, P., Miralles, P., and Resino, S.
- Published
- 2011
- Full Text
- View/download PDF
5. European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients
- Author
-
Guzmán-Fulgencio, M, Rallón, N, Berenguer, J, Fernández-Rodríguez, A, Soriano, V, Miralles, P, Jiménez-Sousa, M A, Restrepo, C, López, J C, García-Álvarez, M, Aldámiz, T, Benito, J M, and Resino, S
- Published
- 2014
- Full Text
- View/download PDF
6. IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients
- Author
-
Jiménez-Sousa, M. A., Berenguer, J., Fernández-Rodríguez, A., Micheloud, D., Guzmán-Fulgencio, M., Miralles, P., Pineda-Tenor, D., García–Álvarez, M., López, J. C., Aldámiz-Echevarria, T., Carrero, A., and Resino, S.
- Published
- 2014
- Full Text
- View/download PDF
7. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients
- Author
-
Jiménez-Sousa, M. A., Berenguer, J., Rallón, N., Guzmán-Fulgencio, M., López, J. C., Soriano, V., Fernández-Rodríguez, A., Cosín, J., Restrepo, C., García-Álvarez, M., Miralles, P., Benito, J. M., and Resino, S.
- Published
- 2013
- Full Text
- View/download PDF
8. Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients
- Author
-
Guzmán-Fulgencio, M., primary, Berenguer, J., additional, Pineda-Tenor, D., additional, Jiménez-Sousa, M. A., additional, García-Álvarez, M., additional, Aldámiz-Echevarria, T., additional, Carrero, A., additional, Diez, C., additional, Tejerina, F., additional, Vázquez, S., additional, Briz, V., additional, and Resino, S., additional
- Published
- 2014
- Full Text
- View/download PDF
9. IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients
- Author
-
Jiménez-Sousa, M. A., primary, Berenguer, J., additional, Fernández-Rodríguez, A., additional, Micheloud, D., additional, Guzmán-Fulgencio, M., additional, Miralles, P., additional, Pineda-Tenor, D., additional, García-Álvarez, M., additional, López, J. C., additional, Aldámiz-Echevarria, T., additional, Carrero, A., additional, and Resino, S., additional
- Published
- 2013
- Full Text
- View/download PDF
10. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus‐/HCV‐coinfected patients
- Author
-
Jiménez‐Sousa, M. A., primary, Berenguer, J., additional, Rallón, N., additional, Guzmán‐Fulgencio, M., additional, López, J. C., additional, Soriano, V., additional, Fernández‐Rodríguez, A., additional, Cosín, J., additional, Restrepo, C., additional, García‐Álvarez, M., additional, Miralles, P., additional, Benito, J. M., additional, and Resino, S., additional
- Published
- 2012
- Full Text
- View/download PDF
11. Association of torque teno virus (TTV) and torque teno mini virus (TTMV) with liver disease among patients coinfected with human immunodeficiency virus and hepatitis C virus
- Author
-
García-Álvarez, M., primary, Berenguer, J., additional, Álvarez, E., additional, Guzmán-Fulgencio, M., additional, Cosín, J., additional, Miralles, P., additional, Catalán, P., additional, López, J. C., additional, Rodríguez, J. Ma, additional, Micheloud, D., additional, Muñoz-Fernández, Ma Á., additional, and Resino, S., additional
- Published
- 2012
- Full Text
- View/download PDF
12. European mitochondrial haplogroups are not associated with hepatitis C virus ( HCV) treatment response in HIV/ HCV-coinfected patients.
- Author
-
Guzmán‐Fulgencio, M, Rallón, N, Berenguer, J, Fernández‐Rodríguez, A, Soriano, V, Miralles, P, Jiménez‐Sousa, MA, Restrepo, C, López, JC, García‐Álvarez, M, Aldámiz, T, Benito, JM, and Resino, S
- Subjects
- *
ANTIVIRAL agents , *CHI-squared test , *FISHER exact test , *GENETIC polymorphisms , *HEPATITIS C , *HIV infections , *MITOCHONDRIA , *RESEARCH funding , *U-statistics , *LOGISTIC regression analysis , *RETROSPECTIVE studies , *DATA analysis software - Abstract
Objectives Mitochondria are multifunctional organelles with a key role in the innate immune response against viral infections. Mitochondrial DNA ( mtDNA) haplogroups have been related to AIDS progression and CD4 T-cell recovery in HIV-infected patients, and to a delay in the development of liver fibrosis in HIV/hepatitis C virus ( HCV)-coinfected patients. We performed a study to investigate whether mtDNA haplogroups may be associated with HCV treatment response in HIV/ HCV-coinfected patients on pegylated interferon ( pegIFN) plus ribavirin ( RBV). Methods We performed a retrospective study in 304 patients who completed a course of HCV therapy. mtDNA polymorphisms were genotyped using Sequenom's MassARRAY platform. The interleukin-28B ( IL-28B) polymorphism (rs12980275) was genotyped using the GoldenGate® assay. Sustained virological response ( SVR) was defined as an undetectable HCV viral load at week 24 after the end of treatment. The statistical analysis was carried out using on-treatment data. Results The SVR rates were 52.6% (160 of 304) for all patients, and 37.8% (46 of 201) for patients with HCV genotype 1 or 4 vs. 81.4% (83 of 102) for patients with HCV genotype 2 or 3 ( P < 0.001). No significant associations were found between mtDNA haplogroup and SVR when all patients were included in the analysis and when patients were stratified by HCV genotype (i.e. those with genotypes 1/4 and 2/3 analysed separately) or IL-28B rs12980275 genotype. Conclusions European mtDNA haplogroups were not related to HCV treatment response in HIV/ HCV-coinfected patients on pegIFN-α/ RBV therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. IL28 RA polymorphism (rs10903035) is associated with insulin resistance in HIV/ HCV-coinfected patients.
- Author
-
Jiménez‐Sousa, M. A., Berenguer, J., Fernández‐Rodríguez, A., Micheloud, D., Guzmán‐Fulgencio, M., Miralles, P., Pineda‐Tenor, D., García–Álvarez, M., López, J. C., Aldámiz‐Echevarria, T., Carrero, A., and Resino, S.
- Subjects
INTERLEUKINS ,INSULIN resistance ,HEPATITIS C virus ,VIRUS diseases ,GENETIC polymorphisms ,HIV ,HEPATIC fibrosis ,PATIENTS - Abstract
Hepatitis C virus ( HCV) infection is associated with insulin resistance ( IR), although mechanisms leading to IR in these patients are not completely understood. The aim of this study was to evaluate the association of interleukin 28B ( IL28B) and interleukin 28 receptor alpha ( IL28RA) polymorphisms with IR among human immunodeficiency virus (HIV)/HCV-coinfected patients. We carried out a cross-sectional study on 203 patients. IL28B (rs8099917) and IL28RA (rs10903035) polymorphisms were genotyped by GoldenGate
® assay. IR was defined as homeostatic model assessment ( HOMA) values ≥3.00. Univariate and multivariate generalized linear models (GLM) were used to compare HOMA values and the percentage of patients with IR according to IL28B and IL28RA genotypes. In total, 32% ( n = 65/203) of the patients had IR. IL28B rs8099917 TT was not significantly associated with HOMA values and IR. In contrast, rs10903035 AA was significantly associated with high HOMA values taking into account all patients ( P = 0.024), as well as the subgroups of patients with significant fibrosis ( P = 0.047) and infected with HCV genotype 3 ( P = 0.024). Additionally, rs10903035 AA was significantly associated with IR ( HOMA ≥3.00) in all patients (adjusted odds ratio ( aOR) = 2.02; P = 0.034), in patients with significant fibrosis ( aOR = 2.86; P = 0.039) and HCV genotype 3 patients ( aOR = 4.89; P = 0.031). In conclusions, IL28RA polymorphism (rs10903035) seems to be implicated in the glucose homeostasis because AA genotype increases the likelihood of IR, but this association was different depending on hepatic fibrosis and HCV genotype. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
14. IL28 RA polymorphism is associated with early hepatitis C virus ( HCV) treatment failure in human immunodeficiency virus-/ HCV-coinfected patients.
- Author
-
Jiménez‐Sousa, M. A., Berenguer, J., Rallón, N., Guzmán‐Fulgencio, M., López, J. C., Soriano, V., Fernández‐Rodríguez, A., Cosín, J., Restrepo, C., García‐Álvarez, M., Miralles, P., Benito, J. M., and Resino, S.
- Subjects
HEPATITIS C treatment ,INTERFERONS ,RIBAVIRIN ,GENETIC polymorphisms ,DISEASE relapse ,HIV-positive persons ,ALLELES - Abstract
Due to the poor rate of response to hepatitis C virus (HCV) with pegylated interferon and ribavirin treatment in HCV/HIV coinfected patients, key factors for predicting failure would be useful. We performed a retrospective study on 291 patients on HCV treatment, who had early virological response (EVR) data. IL28B and IL28RA polymorphisms were performed using the GoldenGate
® assay. Unfavourable genotypes at IL28B (rs12980275 AG/GG and rs8099917 GT/GG) and an unfavourable allele at IL28RA (rs10903035 G) were associated with early treatment failure. However, only the rs12980275 AG/GG genotype and rs10903035 G allele remained independently associated with early failure in the overall population (OR = 4.15 (95% CI = 1.64-10.54) and OR = 2.00 (95% CI = 1.19-3.36), respectively) as well as in GT1/4 patients (OR = 5.07 (95% CI = 1.81-14.22) and OR = 2.03 (95% CI = 1.13-3.66), respectively). Next, a decision tree showed early treatment failure increased from 37.1% to 65.5% when the unfavourable rs12980275 AG/GG and rs10903035 AG/GG genotypes and HCV-RNA≥ 500.000 IU/mL were taken into account in GT1/4 patients. In contrast, the failure rate decreased from 37.1% to 11.9% when the favourable rs12980275 AA and rs10903035 AA genotypes were detected. The percentage of patients correctly classified was 78.4%, and AUROC was 0.802 ± 0.028. Regarding GT3 patients, the presence of the GCGCA haplotype (all unfavourable alleles) was associated with early treatment failure, while no association was observed for the IL28B polymorphisms. In conclusion, the IL28RA polymorphism was associated with early treatment failure independently of the IL28B SNPs. The combination of IL28B and IL28RA polymorphisms might be a valuable tool for predicting early treatment failure before starting HCV treatment. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
15. IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.
- Author
-
Guzmán-Fulgencio M, Berenguer J, García-Alvarez M, Fernández-Rodríguez A, Jiménez-Sousa MA, Alvarez E, Micheloud D, López JC, Miralles P, Cosín J, Catalán P, Resino S, Guzmán-Fulgencio, María, Berenguer, Juan, García-Álvarez, Mónica, Fernández-Rodríguez, Amanda, Jiménez-Sousa, María A, Alvarez, Emilio, Micheloud, Dariela, and López, Juan Carlos
- Abstract
Objective: To evaluate the association of IL28B polymorphisms and severity of liver disease among human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients.Methods: We carried out a cross-sectional study on 223 patients. Liver biopsies were evaluated according to Metavir score. IL28B polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) were genotyped using GoldenGate(®) assay.Results: IL28B polymorphisms were in strong linkage disequilibrium, especially the couples rs12980275/rs11881222 and rs8099917/rs7248668. For all patients, the rs12980275 A allele increased the odds for significant fibrosis (F ≥ 2) odds ratio (OR) = 1.68; p = 0.018) and more rapid fibrosis progression (FPR ≥ 0.075 fibrosis units/year) (OR = 1.64; p = 0.035), and decreased the odds for liver steatosis (OR = 0.61; p = 0.046). Furthermore, the rs8099917 T allele increased the odds for F ≥ 2 (OR = 1.93; p = 0.020), FPR ≥ 0.075 (OR = 2.08; p = 0.021), and elevated ALT (≥80 IU/l) (OR = 1.78; p = 0.048). For HCV-genotype 1 patients, rs12980275 A and rs8099917 T alleles decreased the odds for liver steatosis (OR = 0.22; p < 0.001 and OR = 0.39; p = 0.048; respectively). For HCV-genotype 3 patients, the rs12980275 A allele increased the odds for F ≥ 2 ((OR = 6.30; p = 0.012), FPR ≥ 0.075 (OR = 6.40; p = 0.025), and elevated ALT (OR = 4.12; p = 0.037); and the rs8099917 T allele also increased the odds for F ≥ 2 (OR = 7.56; p = 0.027), FPR ≥ 0.075 (OR = 50.8; p = 0.012), and elevated ALT (OR = 5.39; p = 0.043). However, we did not find significant trends in patients infected with HCV-genotype 4.Conclusion: The major alleles of IL28B (rs12980275 A, rs11881222 A, rs8099917 T, and rs7248668 G) are associated with increased odds of liver disease severity in HIV patients infected with HCV-genotype 3. In contrast, HCV-genotype 1 patients carrying the major alleles of IL28B polymorphisms had lower odds for liver steatosis. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
16. Plasma IL-6 and IL-9 predict the failure of interferon-[alpha] plus ribavirin therapy in HIV/HCV-coinfected patients.
- Author
-
Guzmán-Fulgencio M, Jiménez JL, Berenguer J, Fernández-Rodríguez A, López JC, Cosín J, Miralles P, Micheloud D, Muñoz-Fernández MA, and Resino S
- Published
- 2012
17. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C
- Author
-
Jiménez-Sousa María A, Fernández-Rodríguez Amanda, Guzmán-Fulgencio María, García-Álvarez Mónica, and Resino Salvador
- Subjects
meta-analysis ,systematic review ,interleukin 28B ,HCV ,polymorphisms ,Medicine - Abstract
Abstract Background Since 2009, several studies have identified single-nucleotide polymorphisms (SNPs) near the gene encoding for interleukin (IL)-28 (IL28B) that are strongly associated with spontaneous and treatment-induced hepatitis C virus (HCV) clearance. Because this large amount of data includes some inconsistencies, we consider assessment of the global estimate for each SNP to be essential. Methods Relevant studies assessing IL28B polymorphisms associated with sustained virologic response (SVR) and spontaneous clearance (SC) were identified from a literature search of PubMed up to 9 July, 2012. Studies were eligible studies if they included patients infected with HCV or HCV/HIV, or assessed any SNP located within or near the IL28B gene, SVR data available under standard treatment, and/or SC data in patients with acute HCV infection. Pooled odds ratios were estimated by fixed or random effects models when appropriate. Variables such as HCV genotype, ethnicity, and type of co-infection were studied. Results Of 282 screened studies, 67 were selected for SVR and 10 for SC. In total, 20,163 patients were studied for SVR and 3,554 for SC. For SVR, we found that all SNPs showed strong associations in patients with HCV genotypes 1 and 4, whereas the pooled ORs were almost three times lower for genotypes 2 and 3 (rs12979860 and rs8099917). Regarding ethnicity, the SNP most associated with SVR was rs12979860 in white patients, whereas in East Asians it seemed to be rs8099917. The most studied SNP (rs12979860) showed similar results for patients co-infected with HCV/HIV, as for those infected with HCV only. Finally, rs12979860 and rs8099917 both appeared to be associated with SC. Conclusions IL28B polymorphisms influence both the outcome of interferon treatment and the natural clearance of HCV. However we did not identify a universal predictor SNP, as the best genetic markers differed depending on patient ethnicity, genotype, and type of infection. Nevertheless, our results may be useful for more precise treatment decision-making.
- Published
- 2013
- Full Text
- View/download PDF
18. An Exploratory Approach of Clinically Useful Biomarkers of Cvid by Logistic Regression.
- Author
-
Guerra-Galán T, Palacios-Ortega M, Jiménez-Huete A, Guevara-Hoyer K, Cárdenas MC, Villegas-Mendiola Á, Mansilla-Ruíz MD, Subhi-Issa N, de la Fuente-Munoz E, Requejo PM, de la Peña AR, Guzmán-Fulgencio M, Fernández-Arquero M, de Diego RP, and Sánchez-Ramón S
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Logistic Models, Young Adult, Adolescent, Aged, Immunoglobulin kappa-Chains blood, Immunoglobulin kappa-Chains genetics, Sensitivity and Specificity, B-Lymphocytes immunology, Immunoglobulin lambda-Chains, Memory B Cells immunology, Common Variable Immunodeficiency diagnosis, Common Variable Immunodeficiency immunology, Biomarkers
- Abstract
Despite advancements in genetic and functional studies, the timely diagnosis of common variable immunodeficiency (CVID) remains a significant challenge. This exploratory study was designed to assess the diagnostic performance of a novel panel of biomarkers for CVID, incorporating the sum of κ+λ light chains, soluble B-cell maturation antigen (sBCMA) levels, switched memory B cells (smB) and the VISUAL score. Comparative analyses utilizing logistic regression were performed against established gold-standard tests, specifically antibody responses. Our research encompassed 88 subjects, comprising 27 CVID, 23 selective IgA deficiency (SIgAD), 20 secondary immunodeficiency (SID) patients and 18 healthy controls. We established the diagnostic accuracy of sBCMA and the sum κ+λ, achieving sensitivity (Se) and specificity (Spe) of 89% and 89%, and 90% and 99%, respectively. Importantly, sBCMA showed strong correlations with all evaluated biomarkers (sum κ+λ, smB cell and VISUAL), whereas the sum κ+λ was uniquely independent from smB cells or VISUAL, suggesting its additional diagnostic value. Through a multivariate tree decision model, specific antibody responses and the sum κ+λ emerged as independent, signature biomarkers for CVID, with the model showcasing an area under the curve (AUC) of 0.946, Se 0.85, and Spe 0.95. This tree-decision model promises to enhance diagnostic efficiency for CVID, underscoring the sum κ+λ as a superior CVID classifier and potential diagnostic criterion within the panel., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
19. Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies.
- Author
-
García-Bravo L, Calle-Rubio M, Fernández-Arquero M, Mohamed Mohamed K, Guerra-Galán T, Guzmán-Fulgencio M, Rodríguez de la Peña A, Cañizares C, López B, Vadillo C, Matías-Guiu J, Nieto Barbero A, Álvarez-Sala Walther JL, Sánchez-Ramón S, and Ochoa-Grullón J
- Abstract
Introduction: SARS-CoV-2 is a RNA virus that associates with heterogeneous clinical manifestations and complications. Auto-antibodies are identified in approximately 50% of hospitalized COVID-19 patients., Objectives: To determine the global incidence of myositis-related auto-antibodies (non Jo1-RNA synthetases: anti-PL7, anti-PL12, anti-EJ, anti-OJ and RNA-sensor: anti-MDA5) in our laboratory during COVID-19 pandemics, and to describe the clinical and laboratory features of these patients., Study Design: A retrospective study was performed from 2015 to 2021 in a cohort of 444 patients with suspected inflammatory myopathy. The incidence of positive results for the MSA was expressed as absolute value per year for the reference population. Immunoblot analysis, indirect immunofluorescence and HLA typing of 36 patients with positivity for MSAs were collected and analyzed., Results: We observed MSA positive in 28 patients in 2020 and 36 patients in 2021, representing a mean increase of 6-fold respect to previous years since 2015 (range, 0 to 19). In 2020, the most common antibody detected was anti-MDA5 (68%). In contrast, in 2021 the most common antibodies were anti-PL7 and/or anti-PL12 (69%). All patients in 2021 with positive anti-synthetases were fully vaccinated, 4 had previous documented infection, with median time from vaccine to MSA positivity of 5 months. Eight out of 36 patients (22%) reported clinical onset after SARS-CoV-2 vaccination and 6 out of 36 (17%) presented clinical and/or radiological worsening after SARS-CoV-2 vaccination. All patients presented with a known human leukocyte antigen (HLA)-DRB1* allele associated with ASS. The most prevalent alleles identified were DRB1*03:01, DRB1*04, DRB1*11:01, corresponding to 70% (16/23) of our cohort., Conclusions: Our preliminary data show an increased incidence of anti-synthetase antibodies during COVID-19 pandemic and SARS-CoV-2 vaccination associated to HLA DRB1* risk allele. Differential profiles of MSA specificities were observed: mainly against RNA-sensors in 2020 and against RNA-synthetases in 2021. Further studies are needed to support the association between SARS-CoV-2 infection and/or vaccination and the occurrence of this autoimmune syndrome., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2022 Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
20. Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells.
- Author
-
Álvarez-Palomo B, García-Martinez I, Gayoso J, Raya A, Veiga A, Abad ML, Eiras A, Guzmán-Fulgencio M, Luis-Hidalgo M, Eguizabal C, Santos S, Balas A, Alenda R, Sanchez-Gordo F, Verdugo LP, Villa J, Carreras E, Vidal F, Madrigal A, Herrero MJ, Rudilla F, and Querol S
- Subjects
- Blood Banks, HLA Antigens genetics, Haplotypes, Humans, Prospective Studies, Tissue Donors, Induced Pluripotent Stem Cells
- Abstract
Background: iPSC (induced pluripotent stem cells) banks of iPSC lines with homozygous HLA (human leukocyte antigen) haplotypes (haplobanks) are proposed as an affordable and off-the-shelf approach to allogeneic transplantation of iPSC derived cell therapies. Cord blood banks offer an extensive source of HLA-typed cells suitable for reprogramming to iPSC. Several initiatives worldwide have been undertaken to create national and international iPSC haplobanks that match a significant part of a population., Methods: To create an iPSC haplobank that serves the Spanish population (IPS-PANIA), we have searched the Spanish Bone Marrow Donor Registry (REDMO) to identify the most frequently estimated haplotypes. From the top ten donors identified, we estimated the population coverage using the criteria of zero mismatches in HLA-A, HLA-B, and HLA-DRB1 with different stringencies: high resolution, low resolution, and beneficial mismatch., Results: We have calculated that ten cord blood units from homozygous donors stored at the Spanish cord blood banks can provide HLA-A, HLA-B, and HLA-DRB1 matching for 28.23% of the population., Conclusion: We confirm the feasibility of using banked cord blood units to create an iPSC haplobank that will cover a significant percentage of the Spanish and international population for future advanced therapy replacement strategies.
- Published
- 2021
- Full Text
- View/download PDF
21. Algorithm to Study HLA-Antibodies and Selecting Criteria for the Best Haploidentical Donor.
- Author
-
Luis-Hidalgo M, Planelles Silvestre D, Guzmán-Fulgencio M, Castro E, and Solano C
- Published
- 2020
- Full Text
- View/download PDF
22. IL7RA polymorphisms predict the CD4+ recovery in HIV patients on cART.
- Author
-
Guzmán-Fulgencio M, Berenguer J, Jiménez-Sousa MA, Micheloud D, García-Álvarez M, Bellón JM, Aldámiz-Echevarría T, García-Broncano P, Catalán P, Diez C, Pineda-Tenor D, and Resino S
- Subjects
- Adult, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes immunology, Female, Genotype, HIV Infections genetics, HIV Infections immunology, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Polymorphism, Genetic, Polymorphism, Single Nucleotide, Proportional Hazards Models, Retrospective Studies, Spain, Treatment Outcome, Viral Load, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, Receptors, Interleukin-7 genetics, Reverse Transcriptase Inhibitors therapeutic use
- Abstract
Background: The IL7RA polymorphisms have recently been associated with CD4+ T-cell decline in untreated HIV-infected subjects and CD4+ T-cell recovery in patients on combination antiretroviral therapy (cART). The aim of this study was to evaluate whether IL7RA polymorphisms are associated with CD4+ T-cell recovery in HIV-infected patients on long-term cART., Study Design: We performed a retrospective study in 151 naïve cART patients with severe immunodeficiency (CD4+ counts ≤200 cells/mm(3) ). IL7RA polymorphisms' genotyping was performed using Sequenom's MassARRAY platform. The outcome variable was the time to achieve the first value of CD4+ count ≥500 cells/mm(3) during the follow-up., Results: Two different trends of CD4+ T-cell recovery were found in Kaplan-Meier analysis. During the first 48 months, 60 of 151 (39·7%) of the patients reached CD4+ T-cell values ≥500 cells/mm(3) , and no differences were observed between IL7RA genotypes. After the first 48 months of follow-up, 27 of 151 (17·8%) of the patients reached CD4+ T-cell values ≥500 cells/mm(3) , with a different pattern of CD4+ recovery depending on IL7RA genotype. Patients with rs10491434 TT genotype and rs6897932 TT genotype were more likely of achieving CD4+ value ≥500 cells/mm(3) than patients with rs10491434 CT/CC genotype (adjusted hazard ratio (aHR) = 3·59; P = 0·005) and patients with rs6897932 CC/CT genotype (aHR = 11·7; P < 0·001)., Conclusions: The IL7RA polymorphisms seem to be associated with CD4+ T-cell recovery in HIV-infected patients who started cART with severe immunodeficiency, in the second phase of CD4+ T-cell recovery after long-term cART., (© 2015 Stichting European Society for Clinical Investigation Journal Foundation.)
- Published
- 2015
- Full Text
- View/download PDF
23. Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study.
- Author
-
Guzmán-Fulgencio M, Berenguer J, Jiménez-Sousa MA, Pineda-Tenor D, Aldámiz-Echevarria T, García-Broncano P, Carrero A, García-Álvarez M, Tejerina F, Diez C, Vazquez-Morón S, and Resino S
- Subjects
- Adult, Coinfection complications, Coinfection virology, Cross-Sectional Studies, Female, Genetic Predisposition to Disease, HIV, HIV Infections complications, HIV Infections epidemiology, HIV Infections virology, Haplotypes genetics, Hepatitis C, Chronic complications, Hepatitis C, Chronic epidemiology, Hepatitis C, Chronic virology, Humans, Linkage Disequilibrium genetics, Male, Coinfection genetics, Genetic Association Studies, HIV Infections genetics, Hepacivirus physiology, Hepatitis C, Chronic genetics, Polymorphism, Single Nucleotide genetics, Receptors, Interleukin-7 genetics
- Abstract
Background: Interleukin-7 (IL-7) is a critical factor for T cell development and for maintaining and restoring homeostasis of mature T cells. Polymorphisms at α-chain of the IL-7 receptor (IL7R or CD127) gene are related to evolution of HIV-infection, but there are no data concerning the evolution of hepatitis C virus (HCV) infection. The aim of this study was to analyze the association between IL7R polymorphisms and severe liver disease in HCV/HIV coinfected patients., Methods: We performed a cross-sectional study in 220 naïve patients who underwent a liver biopsy. IL7R polymorphisms (rs6897932, rs987106 and rs3194051) were genotyped using the GoldenGate(®) assay. The outcome variables were: (a) liver biopsy: advanced fibrosis (F ≥ 3), severe activity grade (A3); (b) non-invasive indexes: advanced fibrosis (APRI ≥1.5 and FIB-4 ≥3.25). Logistic regression analysis was used to investigate the association between IL7R polymorphisms and outcome variables. This test gives the differences between groups and the odds ratio (OR) for liver disease., Results: Patients with rs6897932 CC genotype had higher likelihood of having A3 than patients with rs6897932 CT/TT (adjusted odds ratio (aOR) = 4.16; p = 0.026). Patients with rs987106 TT genotype had higher odds of having F ≥ 3 (aOR = 3.09; p = 0.009) than rs987106 AA/AT carriers. Finally, patients with rs3194051 AA genotype had higher odds of having severe liver fibrosis (F ≥ 3; APRI ≥1.5, and FIB4 ≥3.25) than patients with rs3194051 AG/GG genotype [aOR = 2.73 (p = 0.010); aOR = 2.52 (p = 0.029); and aOR = 4.01 (p = 0.027); respectively]. The CTA haplotype (comprised of rs6897932, rs987106, and rs3194051) carriers had higher odds of having F ≥ 3 (aOR = 1.85; p = 0.012), APRI ≥1.5 (aOR = 1.94; p = 0.023), and FIB4 ≥3.25 (aOR = 2.47; p = 0.024). Conversely, the CAG haplotype carriers had lower odds of having F ≥ 3 (aOR = 0.48; p = 0.011), APRI ≥1.5 (aOR = 0.48; p = 0.029), and FIB4 ≥3.25 (aOR = 0.29; p = 0.010)., Conclusions: The presence of IL7R polymorphisms seems to be related to severe liver disease in HIV/HCV coinfected patients, because patients with unfavorable IL7R genotypes (rs6897932 CC, rs987106 TT, and rs3194051AA) had a worse prognosis of CHC.
- Published
- 2015
- Full Text
- View/download PDF
24. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients.
- Author
-
Jiménez-Sousa MA, Rallón N, Berenguer J, Pineda-Tenor D, López JC, Soriano V, Guzmán-Fulgencio M, Cosín J, Retana D, García-Álvarez M, Miralles P, Benito JM, and Resino S
- Subjects
- Adult, Alleles, Coinfection drug therapy, Female, Genotype, HIV Infections virology, Haplotypes, Humans, Interferon-alpha therapeutic use, Male, Middle Aged, Multivariate Analysis, Polymorphism, Single Nucleotide, Retrospective Studies, Ribavirin therapeutic use, Antiviral Agents therapeutic use, Coinfection virology, HIV Infections complications, Hepacivirus drug effects, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Toll-Like Receptor 3 genetics
- Abstract
Background: Toll-like receptor-3 (TLR3) is a cellular receptor that may recognize double-stranded RNA (dsRNA) from viruses, resulting in production of proinflammatory cytokines and interferons, which are important for the adaptive immune response., Objectives: To analyze the association between Toll-like receptor-3 (TLR3) polymorphisms (rs3775291 and rs13126816) and virologic response to pegylated interferon-alpha plus ribavirin (pegIFNα/RBV) therapy in HIV/HCV coinfected patients., Study Design: We performed a retrospective study in 321 naïve patients treated with pegIFNα/RBV. Genotyping was performed by using the GoldenGate(®) assay with VeraCode(®). The outcome variables were early virologic response (EVR) and sustained virologic response (SVR)., Results: In a multivariate analysis, rs3775291 A allele decreased the likelihood of achieving EVR (aOR = 0.20; p = 0.018) and SVR (aOR = 0.38; p = 0.024). Regarding rs13126816, the percentage of EVR decreased with each minor A allele (p = 0.034) in HCV-GT2/3 patients, although no significant association was obtained in the multivariate analysis (p = 0.076). Regarding TLR3 haplotypes (comprised of rs3775291 and rs13126816), GT2/3 patients with AA haplotype had decreased odds of achieving EVR (p = 0.030), whereas GG haplotype increased the likelihood (p = 0.018). Regarding SVR, GG haplotype carriers had increased odds of achieving SVR (p = 0.019, p = 0.043 and p = 0.070 for all, GT2/3 and GT1/4 patients, respectively). Besides, GT1/4 patients with GA haplotype had lower odds of achieving SVR (p = 0.039)., Conclusions: Our study shows the first evidence that two TLR3 polymorphisms (rs3775291 and rs13126816) seem to be related to the HCV therapy response in HCV/HIV coinfected patients., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
25. Single nucleotide polymorphisms of CXCL9-11 chemokines are associated with liver fibrosis in HIV/HCV-coinfected patients.
- Author
-
Pineda-Tenor D, Berenguer J, García-Álvarez M, Guzmán-Fulgencio M, Carrero A, Aldámiz-Echevarria T, Tejerina F, Diez C, Jiménez-Sousa MA, Fernández-Rodríguez A, Munoz-Fernandez MA, and Resino S
- Subjects
- Adult, Coinfection complications, Cross-Sectional Studies, Female, Gene Frequency, Genetic Association Studies, Genotype, Genotyping Techniques, Homozygote, Humans, Male, Chemokine CXCL11 genetics, Chemokine CXCL9 genetics, HIV Infections complications, Hepatitis C, Chronic complications, Liver Cirrhosis epidemiology, Liver Cirrhosis genetics, Polymorphism, Single Nucleotide
- Abstract
Background: CXCR3A-associated chemokines (CXCL9-11) are implicated in the pathogenesis of hepatitis C virus (HCV) infection. We analyzed the association between CXCL9-11 polymorphisms and significant liver fibrosis in human immunodeficiency virus (HIV)/HCV-coinfected patients., Methods: We performed a cross-sectional study in 220 patients who were genotyped for CXCL9-11 polymorphisms (CXCL9 rs10336, CXCL10 rs3921, and CXCL11 rs4619915) using GoldenGate assay. Three outcome variables related to liver fibrosis were studied: (1) F ≥ 2; (2) APRI ≥ 2; and (3) FIB-4 ≥ 3.25., Results: The percentage of patients with significant liver fibrosis (F ≥ 2, APRI ≥ 2, and FIB-4 ≥ 3.25) was significantly higher for CXCL9 rs10336 TT (P = 0.046, P = 0.010, and P = 0.046, respectively), CXCL10 rs3921 GG (P = 0.046, P = 0.011, and P = 0.049, respectively), and CXCL11 rs4619915 AA (P = 0.035, P = 0.014, and P = 0.057, respectively) genotypes. Moreover, the greater likelihood of having significant liver fibrosis (F ≥ 2, APRI ≥ 2, and FIB-4 ≥ 3.25) was found in carriers of CXCL9 rs10336 TT and CXCL10 rs3921 GG [adjusted odds ratio (aOR) > 2 (P < 0.05)]. These trends were significantly more pronounced in patients infected with HCV-genotype 1 (GT1) [aOR > 3 (P < 0.05)]. Moreover, TGA haplotype showed higher odds for having values of APRI ≥ 2 (aOR = 2.4; P = 0.012) when we considered all patients. This elevated risk for significant liver fibrosis was better represented in patients infected with HCV-GT1, where TGA haplotype had increased odds for having values of F ≥ 2 (aOR = 1.9; P = 0.045), APRI ≥ 2 (aOR = 3.2; P = 0.009), and FIB-4 ≥ 3.25 (aOR = 3.3; P = 0.026)., Conclusions: The homozygosity for the minor alleles CXCL9 rs10336 (T), CXCL10 rs3921 (G), and CXCL11 rs4619915 (A) is associated with the higher likelihood of significant liver fibrosis in HIV-infected patients coinfected with HCV-GT1.
- Published
- 2015
- Full Text
- View/download PDF
26. rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients.
- Author
-
Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, Carrero A, García-Álvarez M, Aldámiz-Echevarria T, García-Broncano P, Diez C, Guzmán-Fulgencio M, Fernández-Rodríguez A, and Resino S
- Subjects
- Adult, Cholesterol blood, Cross-Sectional Studies, Female, Genotype, HIV, HIV Infections pathology, Hepatitis C, Chronic pathology, Humans, Lipoproteins blood, Male, Triglycerides blood, Dyslipidemias epidemiology, Dyslipidemias genetics, Genetic Predisposition to Disease, Genetic Variation, HIV Infections complications, Hepatitis C, Chronic complications, Transcription Factor 7-Like 2 Protein genetics
- Abstract
Transcription factor 7 like 2 (TCF7L2) rs7903146 polymorphism has been associated with metabolic disturbance and cardiovascular disease. The aim of this study was to analyze the association between TCF7L2 rs7903146 polymorphism and potential disturbances on the lipid profile in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. We performed a cross-sectional study on 263 HIV/HVC-coinfected patients. TCF7L2 polymorphism was genotyped by GoldenGate assay. The analysis was performed by linear and logistic regression under a dominant model of inheritance. The variables analyzed were total cholesterol (TC), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), non-HDL-C, and triglycerides. Patients harboring the rs7903146 TT/TC genotype showed a diminished concentration of TC (p=0.003), LDL-C (p=0.004), HDL-C (p=0.012), and non-HDL-C (p=0.013), a lower percentage of TC≥200 mg/dl (p=0.038), and a higher percentage of HDL≤40 mg/dl (p=0.023). In addition, we observed that rs7903146 was differently related to fasting serum lipid levels according to the HCV-genotype (HCV-GT). With regard to HCV-GT1 patients, the rs7903146 TT/TC genotype was associated with lower levels of HDL-C [adjusted arithmetic mean ratio (aAMR)=0.91; p=0.049] and an elevated percentage of patients with HDL-C≤40 mg/dl [adjusted odds ratio (aOR)=3.26; p=0.003]. For HCV-GT3 patients, the rs7903146 TT/TC genotype was associated with lower serum values of TC (aAMR=0.81; p=0.037), LDL-C (aAMR=0.67; p=0.001), and non-HDL-C (aAMR=0.75; p=0.002) and a reduced percentage of TC≥200 mg/dl (aOR=0.089; p=0.037). In conclusion, the TCF7L2 rs7903146 TT/TC genotype was associated with lower levels of TC, LDL, and HDL in HCV-GT3 patients, and lower levels of HDL-C in HCV-GT1 patients, suggesting a role in cardiovascular disease and a potential use as a biomarker in HIV/HCV-coinfected patients.
- Published
- 2015
- Full Text
- View/download PDF
27. Mitochondrial DNA haplogroups are associated with severe sepsis and mortality in patients who underwent major surgery.
- Author
-
Jiménez-Sousa MA, Tamayo E, Guzmán-Fulgencio M, Heredia M, Fernández-Rodríguez A, Gómez E, Almansa R, Gómez-Herreras JI, García-Álvarez M, Gutiérrez-Junco S, Bermejo-Martin JF, and Resino S
- Subjects
- APACHE, Abdomen surgery, Aged, Aged, 80 and over, Cardiovascular Surgical Procedures adverse effects, Case-Control Studies, Female, General Surgery, Genotype, Haplotypes genetics, Humans, Logistic Models, Male, Medical Records, Middle Aged, Sepsis diagnosis, Spain epidemiology, Survival Rate, Systemic Inflammatory Response Syndrome diagnosis, White People, DNA, Mitochondrial genetics, Sepsis genetics, Sepsis mortality
- Abstract
Objective: To analyse whether mitochondrial DNA (mtDNA) haplogroups are associated with severe sepsis and mortality after major surgery., Methods: We performed a case-control study on 240 cardiac or abdominal surgery patients developing severe sepsis (Case-group) and 267 cardiac or abdominal surgery patients without severe sepsis and with systemic inflammatory response syndrome (SIRS, Control-group). Furthermore, a longitudinal substudy was performed for analysing the survival in septic patients. Only European white patients within the N macro-cluster were included., Results: Case-group underwent cardiac surgery had lower frequencies of cluster HV (p = 0.005) and haplogroup H (p = 0.005) and higher frequencies of cluster JT (p = 0.028) than Control-group; but no significant differences were found for abdominal surgery. Besides, both cluster HV and haplogroup H were associated with decreased odds of severe sepsis (adjusted odds ratio (aOR) = 0.45 (95%CI = 0.25; 0.82); p = 0.009 and aOR = 0.48 (95%CI = 0.26; 0.87); p = 0.015, respectively) among patients underwent cardiac surgery. In Case-group, 45.4% (109/240) patients died with a survival median of 39 (95%CI = 31.4; 46.62) days. When the clusters were examined, 41% (55/134) patients within cluster HV died versus 71.4% (10/14) patients within cluster IWX (p = 0.018). Additionally, patients within cluster IWX had an increased risk of death (adjusted hazard ratio (aHR) = 2.22; (95%CI = 1.14; 4.34); p = 0.019)., Conclusions: European mitochondrial haplogroups might be related to the onset of severe sepsis in patients who underwent major cardiac surgery, but not in patients underwent major abdominal surgery. Besides, mtDNA haplogroups could have influence on mortality in septic patients., (Copyright © 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
28. FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.
- Author
-
Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, García-Alvarez M, Aldámiz-Echevarria T, Carrero A, Vázquez-Morón S, García-Broncano P, Diez C, Tejerina F, Guzmán-Fulgencio M, and Resino S
- Subjects
- Adult, Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Antiviral Agents therapeutic use, Body Mass Index, Coinfection complications, Coinfection metabolism, Cross-Sectional Studies, Female, Genotype, HIV Infections complications, HIV Infections metabolism, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic metabolism, Humans, Insulin Resistance genetics, Male, Metabolic Syndrome complications, Metabolic Syndrome genetics, Middle Aged, Obesity complications, Obesity genetics, Odds Ratio, Ribavirin therapeutic use, Coinfection genetics, Genetic Predisposition to Disease genetics, HIV Infections genetics, Hepatitis C, Chronic genetics, Polymorphism, Single Nucleotide, Proteins genetics
- Abstract
Background: The Fat Mass and Obesity-Associated Protein (FTO) gene rs9939609 single nucleotide polymorphism (SNP) has been associated with obesity, metabolic syndrome, insulin resistance (IR), and type 2 diabetes mellitus in the general population. The aim of our study was to examine for the first time the association of the rs9939609 polymorphism with metabolic disturbances, liver disease and virologic response to hepatitis C virus (HCV) therapy with pegylated-interferon-alpha plus ribavirin (pegIFNα/RBV) in human immunodeficiency virus (HIV)/HCV coinfected patients., Methods: We carried out a cross-sectional study in 261 patients, of whom 178 were subsequently treated with pegIFNα/RBV therapy. FTO rs9939609 and IFNL3 rs12980275 polymorphisms were genotyped by GoldenGate®. The main outcomes were: 1) metabolic disturbances: insulin resistance (homeostatic model assessment (HOMA-IR)) and overweight (body mass index (BMI)); 2) liver disease (Metavir score): significant fibrosis (F ≥2) and steatosis (>10% fatty hepatocytes); and 3) virologic response to HCV treatment: sustained virologic response (SVR)., Results: The rs9939609 AA genotype was associated with higher values of BMI (adjusted arithmetic mean ratio (aAMR) = 1.08; 95% confidence interval (95%CI) = 1.03 to 1.14; P = 0.002) and HOMA-IR (aAMR = 1.32; 95%CI = 1.03 to 1.69; P = 0.027). Patients with an rs9939609 AA genotype had higher likelihoods of achieving values of BMI ≥27.5 kg/m2 (adjusted odds ratio (aOR) = 3.46; 95%CI =1.17 to 10.21; P = 0.024), HOMA-IR ≥2.5 (aOR = 2.09; 95%CI = 1.02 to 4.32; P = 0.045), significant fibrosis (aOR = 2.34; 95%CI =1.02 to 5.36; P = 0.045) and steatosis (aOR = 3.65; 95%CI = 1.29 to 10.36; P = 0.015). The rs9939609 AT/AA genotype decreased the likelihood of achieving SVR (aOR = 0.58; 95%CI = 0.34 to 0.99; P = 0.044). A decision tree was performed with the genotypes of HCV, IFNL3 and FTO. The incorporation of rs9939609 significantly improves the prediction of SVR (P <0.05). The overall accuracy was 68.2%., Conclusions: Patients carrying the unfavourable AT/AA genotype of rs9939609 polymorphism had higher odds of metabolic disturbances and a lower likelihood of achieving successful virologic response to HCV therapy.
- Published
- 2014
- Full Text
- View/download PDF
29. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis.
- Author
-
García-Álvarez M, Pineda-Tenor D, Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, and Resino S
- Subjects
- Hepatitis C, Chronic blood, Hepatitis C, Chronic drug therapy, Humans, Liver Cirrhosis blood, Antiviral Agents therapeutic use, Hepatitis C, Chronic complications, Liver Cirrhosis etiology, Vitamin D blood
- Abstract
Unlabelled: There is growing evidence that vitamin D is related to chronic hepatitis C (CHC) pathogenicity. We analyzed the relationship of vitamin D status with advanced liver fibrosis (ALF) in CHC treatment-naïve patients and sustained virologic response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNα/ribavirin) therapy. We performed a meta-analysis of all eligible studies published to date (April, 2014) in PubMed, SCOPUS, LILACS, and the Cochrane Library, assessing plasma/serum vitamin D levels related to ALF and/or SVR. Pooled odds ratios (ORs) were estimated by either fixed or random effects models. Fourteen studies were selected from the literature search, seven for ALF (1,083 patients) and 11 for SVR (2,672 patients). For liver fibrosis, low vitamin D status was related to a diagnosis of ALF, with the cutoffs of 10 ng/mL (OR=2.37, 95% confidence interval [CI]=1.20, 4.72) and 30 ng/mL (OR=2.22, 95% CI=1.24, 3.97) being significant, and a near-significance for 20 ng/mL (OR=1.44, 95% CI=0.99, 2.12). Regarding SVR, a significant heterogeneity among studies was found (P<0.001), and we only found a significant association with SVR for a vitamin D cutoff of 20 ng/mL (OR=0.53, 95% CI=0.31, 0.91). When meta-analysis was performed excluding the outliers, significant pooled ORs were found for all patients (10 ng/mL [OR=0.48, 95% CI=0.34, 0.67] and 20 ng/mL [OR=0.58, 95% CI=0.45, 0.76]) and GT1/4 patients (10 ng/mL [OR=0.53, 95% CI=0.34, 0.81] and 20 ng/mL [OR=0.54, 95% CI=0.39, 0.74])., Conclusion: Low vitamin D status in CHC patients is associated with a higher likelihood of having ALF and lower odds of achieving SVR following pegIFNα/ribavirin therapy., (© 2014 by the American Association for the Study of Liver Diseases.)
- Published
- 2014
- Full Text
- View/download PDF
30. CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV/HCV-coinfected patients.
- Author
-
Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, Guzmán-Fulgencio M, Aldámiz-Echevarria T, Carrero A, García-Álvarez M, Diez C, Tejerina F, Briz V, and Resino S
- Subjects
- Adult, Alleles, Coinfection drug therapy, Coinfection immunology, Coinfection virology, Female, Genotype, Genotyping Techniques, HIV Infections complications, HIV Infections immunology, Hepatitis C, Chronic complications, Hepatitis C, Chronic immunology, Hepatitis C, Chronic virology, Humans, Interferon-alpha therapeutic use, Male, Retrospective Studies, Ribavirin therapeutic use, Treatment Outcome, Chemokine CXCL10 genetics, Chemokine CXCL11 genetics, Chemokine CXCL9 genetics, HIV Infections drug therapy, Hepatitis C, Chronic drug therapy, Polymorphism, Genetic, Viral Load
- Abstract
Background: The CXCL9, CXCL10 and CXCL11 (CXCL9-11) chemokines play a critical role in eradication of hepatitis C virus (HCV), although HCV-specific immunity often fails to eradicate the HCV, allowing the chronicity of hepatitis C., Objective: To examine the association between CXCL9-11 polymorphisms and the sustained virological response (SVR) following hepatitis C virus (HCV) therapy with pegylated-interferon-alpha plus ribavirin in HIV/HCV-coinfected patients., Study Design: We performed a retrospective study in 176 naïve patients who started HCV treatment. The CXCL9 rs10336, CXCL10 rs3921 and CXCL11 rs4619915 polymorphisms were genotyped by GoldenGate(®) assay. Genetic data were analyzed under recessive inheritance model. The SVR was defined as undetectable HCV viremia through 24 weeks after the end of HCV treatment., Results: In the intention-to-treat analysis, the SVR rate was higher in HCV genotype 1/4 (GT1/4) patients carrying rs10336 TT (p=0.042), rs3921 GG (p=0.021), and rs4619915 AA (p=0.024) genotypes; and they had higher likelihood of achieving SVR (adjusted odds ratio (aOR)=3.26 (p=0.038), aOR=4.21 (p=0.019), and aOR=4.08 (p=0.022), respectively). For CXCL haplotype analysis (CXCL9/rs10336, CXCL10/rs3921, and CXCL11/rs4619915), the TGA haplotype (favorable alleles) had better odds of achieving SVR than the CCG haplotype (unfavorable alleles) in GT1/4patients (OR=2.69; p=0.003). No significant results were found in GT2/3 patients. Moreover, similar results were obtained in the on-treatment analysis., Conclusions: The presence of homozygous for the minor allele of CXCL9 rs10336, CXCL10 rs3921 and CXCL11 rs4619915 was related to higher likelihoods of achieving the HCV clearance after pegIFNα/ribavirin therapy in HIV infected patients coinfected with HCV GT1/4., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
31. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy.
- Author
-
Fernández-Rodríguez A, Berenguer J, Rallón N, Jiménez-Sousa MA, López JC, Soriano V, García-Álvarez M, Cosín J, Martínez P, Guzmán-Fulgencio M, Miralles P, Miguel Benito J, and Resino S
- Subjects
- Adult, Animals, Drug Therapy, Combination, Female, Follow-Up Studies, Hepacivirus isolation & purification, Humans, Interferon-alpha therapeutic use, Interferons, Interleukins genetics, Male, Middle Aged, RNA, Viral blood, Retrospective Studies, Ribavirin therapeutic use, Time, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, HIV Infections complications, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, PPAR gamma genetics, Polymorphism, Single Nucleotide
- Abstract
Objectives: To analyze whether peroxisome proliferator-activated receptor gamma (PPARγ2) rs1801282 (Pro12Ala) polymorphism is associated with the response to pegylated-interferon-alpha plus ribavirin treatment in HIV/hepatitis C virus (HCV)-coinfected patients, and whether it is able to predict the outcome of HCV treatment., Design: Retrospective follow-up study., Methods: Two hundred eighty-five naive patients, who started HCV-treatment, were genotyped for PPARγ2 and interleukin 28B polymorphisms. Genetic data were analyzed under dominant inheritance model. Sustained virological response (SVR) was defined as undetectable HCV viremia through 24 weeks after the end of HCV treatment., Results: The variables significantly associated with SVR in a multivariate analysis were HCV-genotype (GT) 3 {adjusted odds ratio [aOR] = 7.66 [95% of confidence interval (95% CI): 3.96 to 14.81] P < 0.001}, HCV-viremia <500,000 IU/mL [aOR = 2.20 (95% CI: 1.16 to 4.15] P = 0.015), no/mild liver fibrosis (F < 2) [aOR = 1.92 (95% CI: 1.08 to 3.42) P = 0.026], IL28B rs12980275 AA genotype [aOR = 2.70 (95% CI: 1.54 to 4.71) P < 0.001], and PPARγ2 rs1801282 CG/GG genotype [aOR = 2.93 (95% CI: 1.27 to 6.72) P = 0.011]. When PPARγ2 rs1801282 genotype was included in a decision tree analysis, HCV-GT3 patients with CG/GG genotype had increased SVR from 80.3% to 100%. In GT1/4 patients, rs12980275 AA carriers had increased SVR from 58.7% to 78.6%, and rs12980275 AG/GG carriers had increased SVR from 28.7% to 35.7%. The overall percentage of patients correctly classified was 71.6% and the area under the receiver operating characteristic curves was 0.766 ± 0.028., Conclusions: The presence of PPARγ2 rs1801282 G allele (Ala variant) was associated with increased odds for achieving SVR in HIV/HCV-coinfected patients on HCV treatment.
- Published
- 2014
- Full Text
- View/download PDF
32. Relationship between European mitochondrial haplogroups and chronic renal allograft rejection in patients with kidney transplant.
- Author
-
Jiménez-Sousa MA, Tamayo E, Guzmán-Fulgencio M, Fernández-Rodríguez A, Heredia-Rodriguez M, García-Álvarez M, Bermejo-Martin JF, Pineda-Tenor D, Ruiz-Granado P, Alvarez-Fuente E, Gómez-Sanchez E, Gómez-Herreras JI, and Resino S
- Subjects
- Adult, DNA, Mitochondrial genetics, Female, Graft Rejection genetics, Haplotypes genetics, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Retrospective Studies, White People, Kidney Transplantation
- Abstract
Mitochondrial DNA variants may contribute to differences in mitochondrial function, leading to an altered immune system. The aim of this study was to analyze the relationship between mtDNA haplogroups and the development of chronic allograft dysfunction in patients with kidney transplant. A retrospective observational study was carried out on 261 patients who received kidney transplant (114 had stable transplant and 147 patients developed chronic allograft dysfunction). DNA samples were genotyped for 14 mtDNA polymorphisms by using Sequenom's MassARRAY platform (San Diego, CA, USA). Only European white patients within the N macro-cluster were included. Patients with haplogroups V (odds ratio (OR)=0.32; p=0.037) and J (OR=0.36; p=0.038) showed lower odds for developing CRAD than patients with haplogroup H. After adjusting for the most significant variables, haplogroups V and J tended to statistical significance (p=0.091 and p=0.067 respectively). This is a preliminary study in which mtDNA haplogroups seem to be implicated in susceptibility or protection for developing chronic allograft dysfunction.
- Published
- 2014
- Full Text
- View/download PDF
33. SLC30A8 rs13266634 polymorphism is related to a favorable cardiometabolic lipid profile in HIV/hepatitis C virus-coinfected patients.
- Author
-
Pineda-Tenor D, Micheloud D, Berenguer J, Jiménez-Sousa MA, Fernández-Rodríguez A, García-Broncano P, Guzmán-Fulgencio M, Diez C, Bellón JM, Carrero A, Aldámiz-Echevarria T, García-Álvarez M, and Resino S
- Subjects
- Adult, Cross-Sectional Studies, Dyslipidemias epidemiology, Female, Genotyping Techniques, HIV Infections pathology, Hepatitis C, Chronic pathology, Humans, Male, Zinc Transporter 8, Cation Transport Proteins genetics, Dyslipidemias genetics, HIV Infections complications, Hepatitis C, Chronic complications, Insulin Resistance genetics, Lipids blood, Polymorphism, Single Nucleotide
- Abstract
Objective: To analyze the relationship of SLC30A8 rs13266634 polymorphism with insulin resistance and dyslipidemia in HIV/hepatitis C virus (HCV)-coinfected patients., Design: Cross-sectional study in 260 HIV/HVC-coinfected patients., Methods: SLC30A8 polymorphisms were genotyped by GoldenGate assay. Genetic data were analyzed under the dominant inheritance model (CT/TT versus CC). Cholesterol, triglycerides, high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), LDL-C/HDL-C, atherogenic index, and homeostatic model assessment of insulin resistance (HOMA-IR) values were assayed for each genotype., Results: rs13266634 CT/TT carriers had higher serum values of HDL-C (P = 0.014) and lower values of LDL-C/HDL-C (P = 0.036) and atherogenic index (P = 0.011) than CC carriers. Additionally, rs13266634 CT/TT carriers had lower percentage of HDL 35 mg/dl or less (P = 0.050) and higher percentage of LDL/HDL at least 3 (P = 0.091) and atherogenic index at least 3.5 (P = 0.003) than CC carriers. When adjusted regression analysis was performed, rs13266634 CT/TT genotype was associated with high serum values of HDL-C [arithmetic mean ratio (AMR) = 1.10 (95% confidence interval, CI = 1.03-1.19) P = 0.006], and low values of LDL-C/HDL-C [AMR = 0.88 (95% CI = 0.79-0.99) P = 0.045] and atherogenic index [AMR = 0.89 (95% CI = 0.81-0.98) P = 0.024]. For categorical outcomes, rs13266634 CT/TT carriers had lower significant likelihood of having atherogenic index at least 3.5 [odds ratio = 0.47 (95% CI = 0.26-0.83) P = 0.009], and very close to significance for LDL-C/HDL-C at least 3 [odds ratio = 0.52 (95% CI = 0.27-1.02) P = 0.056], supporting the protective effect of the CT/TT genotypes. No significant relationship was observed between rs13266634 and HOMA-IR values., Conclusion: rs13266634 CT/TT genotype was associated to higher levels of HDL-C and lower values of cardiovascular risk indices (LDL-C/HDL-C and atherogenic index), but there was a lack of association with HOMA-IR values. Thus, rs13266634 polymorphism might play a significant role in lipid metabolism and cardiovascular risk in HIV/HCV-coinfected patients.
- Published
- 2014
- Full Text
- View/download PDF
34. Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients.
- Author
-
Guzmán-Fulgencio M, García-Álvarez M, Berenguer J, Jiménez-Sousa MÁ, Cosín J, Pineda-Tenor D, Carrero A, Aldámiz T, Alvarez E, López JC, and Resino S
- Subjects
- Adult, Antiviral Agents therapeutic use, Cross-Sectional Studies, Female, HIV Infections virology, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Humans, Liver Cirrhosis virology, Logistic Models, Male, Middle Aged, Vitamin D analogs & derivatives, Vitamin D blood, Vitamin D Deficiency metabolism, HIV Infections metabolism, Hepatitis C, Chronic metabolism, Liver Cirrhosis metabolism, Vitamin D Deficiency virology
- Abstract
Objective: To study the association of plasma 25-hydroxy vitamin D (25(OH)D) levels in HIV/HCV coinfected patients with severity of liver disease and virological response to hepatitis C virus (HCV) therapy with pegylated-interferon-alpha plus ribavirin (pegIFNα/RBV)., Methods: A cross-sectional study in 174 HIV/HCV coinfected patients that underwent a liver biopsy previously to start HCV therapy and a retrospective study of 125 of them. Plasma 25(OH)D levels were quantified by enzyme immunoassay. Liver biopsies were evaluated by METAVIR score. A sustained virological response (SVR) was defined as an undetectable serum HCV viral load (<10 IU/mL) up through 24 weeks after the end of HCV treatment., Results: The median of plasma 25(OH)D level was 48 nmol/L (p25th: 32.5; p75th: 56.1) and 27 (15.5%) had 25(OH)D deficiency (<25 nmol/L). The percentage of 25(OH)D deficiency was higher in patients with significant fibrosis (F ≥ 2) (92.6% vs. 57.1%; p = 0.010) and moderate necroinflammatory activity grade (A ≥ 2) (85.2% vs. 60%; p = 0.043). However, adjusted logistic regression analyses showed that 25(OH)D deficiency was only associated with severity of liver disease [F ≥ 2 (OR = 8.47 (95% of confidence interval (CI) = 1.88; 38.3); p = 0.005) and A ≥ 2 (OR = 3.25 (95%CI = 1.06; 10.1); p = 0.040)]. Moreover, any significant relationship was found between 25(OH)D deficiency and SVR after HCV therapy., Conclusion: Plasma 25(OH)D deficiency was associated with liver disease severity in HIV/HCV coinfected patients, but it was not associated with HCV treatment failure., (Copyright © 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
35. ACSM4 polymorphisms are associated with rapid AIDS progression in HIV-infected patients.
- Author
-
Guzmán-Fulgencio M, Jiménez JL, Jiménez-Sousa MA, Bellón JM, García-Álvarez M, Soriano V, Gijón-Vidaurreta P, Bernal-Morell E, Viciana P, Muñoz-Fernández MÁ, and Resino S
- Subjects
- Adult, Aged, Aged, 80 and over, CD4 Lymphocyte Count, Case-Control Studies, Coenzyme A Ligases physiology, Cross-Sectional Studies, Disease Progression, Female, HIV Infections physiopathology, HIV Long-Term Survivors, Humans, Male, Middle Aged, Young Adult, Coenzyme A Ligases genetics, HIV Infections genetics, Polymorphism, Single Nucleotide genetics
- Abstract
: Our aim was to explore the association among ACSM4 and PECI polymorphisms and AIDS progression in 454 HIV-infected patients never treated with antiretroviral drugs (146 long-term nonprogressors, 228 moderate progressors, and 80 rapid progressors). For ACSM4 polymorphisms, rs7137120 AA/AG and rs7961991 CC/CT genotypes had higher odds of having a rapid AIDS progression [odds ratio (OR) = 3.21; 95% of confidence interval (95% CI) = 1.26 to 8.16; P = 0.014 and OR = 3.60; 95% CI = 1.38 to 9.36; P = 0.009, respectively]. Additionally, the ACSM4 haplotype integrated for both rs7961991 A and rs7137120 C alleles had higher odds of having a rapid AIDS progression (OR = 2.85; 95% CI = 1.28 to 6.25; P = 0.010). For PECI polymorphisms, no significant associations were found. In conclusion, ACSM4 polymorphisms might play a significant role in AIDS progression.
- Published
- 2014
- Full Text
- View/download PDF
36. Prediction of hepatic fibrosis in patients coinfected with HIV and hepatitis C virus based on genetic markers.
- Author
-
Fernández-Rodríguez A, Berenguer J, Jiménez-Sousa MA, Guzmán-Fulgencio M, Micheloud D, Miralles P, López JC, Bellón JM, Aldamiz-Echevarria T, García-Broncano P, Carrero A, Alvarez E, and Resino S
- Subjects
- Adolescent, Adult, Coinfection complications, Female, Follow-Up Studies, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Prognosis, Retrospective Studies, Young Adult, Genetic Markers, HIV Infections complications, Hepatitis C, Chronic complications, Liver Cirrhosis diagnosis, Liver Cirrhosis genetics
- Abstract
Objective: To assess the ability of the cirrhosis risk score (CRS) to predict liver fibrosis progression in HIV/hepatitis C virus (HCV)-coinfected patients., Design: Retrospective follow-up study., Methods: Based on a minimum follow-up time of 10 years with HCV infection, 190 HIV/HCV-coinfected patients were classified according to their METAVIR score: (1) 25 nonprogressor patients who did not develop fibrosis (F0) and (2) 165 progressor patients who developed fibrosis (F ≥ 1). Seven polymorphisms of CRS signature and IL28B genotype were performed using the GoldenGate assay. The CRS signature was calculated by naive Bayes formula as previously described., Results: Nonprogressors had CRS values significantly lower than progressors (0.61 versus 0.67; P = 0.043). Among the progressors, we observed similar CRS values through all the fibrosis stages (F1/F2/F3/F4). The percentage of patients with CRS > 0.70 (high risk of developing fibrosis) was higher in progressors than in nonprogressors; but the percentages with values between 0.50 and 0.70 (intermediate risk) and <0.50 (low risk) were quite similar for each of the fibrosis stages (P = 0.047). The area under the receiver-operating characteristic curve of CRS for discriminating nonprogressor versus progressor was 0.625 (P = 0.043). When clinical variables were considered (age at HCV infection, intravenous drug use, gender, IL28B, and HCV genotype), the area under the receiver-operating characteristic curve of CRS improved up to 0.739 (P < 0.001)., Conclusions: CRS itself seems not to be a good marker for identifying HIV/HCV-coinfected patients who are at high risk of developing liver fibrosis. However, CRS score coupled with clinical factors might help to distinguish between nonprogressors and progressors patients.
- Published
- 2013
- Full Text
- View/download PDF
37. European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy.
- Author
-
Guzmán-Fulgencio M, Berenguer J, Micheloud D, Fernández-Rodríguez A, García-Álvarez M, Jiménez-Sousa MA, Bellón JM, Campos Y, Cosín J, Aldámiz-Echevarría T, Catalán P, López JC, and Resino S
- Subjects
- Adult, CD4 Lymphocyte Count, Female, Follow-Up Studies, Haplotypes, Humans, Male, Middle Aged, Retrospective Studies, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active, CD4-Positive T-Lymphocytes immunology, DNA, Mitochondrial genetics, HIV Infections drug therapy, HIV Infections immunology
- Abstract
Background: There is substantial interindividual variability in the rate and extent of CD4+ T cell recovery after starting combination antiretroviral therapy (cART). The aim of our study was to determine whether mitochondrial DNA (mtDNA) haplogroups are associated with recovery of CD4+ in HIV-infected patients on cART., Methods: We carried out a retrospective study on 275 cART-naive patients with CD4+ counts <350 cells/mm(3), who were followed-up during at least 24 months after initiating cART. mtDNA genotyping was performed by Sequenom's MassARRAY platform., Results: Patients within cluster JT and haplogroup J had a lower chance of achieving a CD4+ count ≥500 cells/mm(3) than patients within cluster HV and haplogroup H [hazard ratio (HR) = 0.68 (P = 0.058) and HR = 0.48 (P = 0.010), respectively]. The time of follow-up during which the CD4+ count was ≥500 cells/mm(3) was longer in haplogroups HV and H than in haplogroups JT and J [20 months versus 6.2 months (P = 0.029) and 20 months versus 0 months (P = 0.024), respectively]. Additionally, haplogroups HV and H had greater chances of achieving a CD4+ count ≥500 cells/mm(3) during at least 12, 36, 48 and 60 months post-cART initiation compared with patients within haplogroups JT and J. Patients within haplogroup T only had a lesser chance of achieving a CD4+ count ≥500 cells/mm(3) during at least 48 months and 60 months post-cART initiation., Conclusion: European mitochondrial haplogroups might influence CD4+ recovery in HIV-infected patients following initiation with cART. Haplogroups J and T appear to be associated with a worse profile of CD4+ recovery, whereas haplogroup H was associated with a better CD4+ reconstitution.
- Published
- 2013
- Full Text
- View/download PDF
38. Mitochondrial haplogroups are associated with clinical pattern of AIDS progression in HIV-infected patients.
- Author
-
Guzmán-Fulgencio M, Jiménez JL, García-Álvarez M, Bellón JM, Fernández-Rodriguez A, Campos Y, Rodríguez C, González-Garcia J, Riera M, Viciana P, Muñoz-Fernández MÁ, and Resino S
- Subjects
- Acquired Immunodeficiency Syndrome drug therapy, Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, DNA, Mitochondrial analysis, Disease Progression, Female, Genotype, Humans, Male, Middle Aged, Mitochondria metabolism, Polymorphism, Single Nucleotide, Reactive Oxygen Species metabolism, Acquired Immunodeficiency Syndrome genetics, Acquired Immunodeficiency Syndrome physiopathology, DNA, Mitochondrial genetics, Haplotypes, Mitochondria genetics
- Abstract
We performed a cross-sectional study in 469 HIV-infected patients, whose mitochondrial haplogroups were genotyped to study their association with the clinical pattern of AIDS progression. The chance of not having an AIDS progression was 1.45 [95% of confidence interval (CI) = 1.02 to 2.05, P = 0.035) times greater in patients with cluster HV and 1.51 (95% CI = 1.06 to 2.18, P = 0.021) times greater in patients with haplogroup H. However, we only found significant values for haplogroup H (odds ratio = 1.52, 95% CI = 1.01 to 2.32, P = 0.049) in an ordinal logistic regression adjusted by gender, age at HIV infection, intravenous drug users, and hepatitis C virus infection. These data suggest that mitochondrial haplogroups might play a significant role in AIDS progression.
- Published
- 2013
- Full Text
- View/download PDF
39. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy.
- Author
-
Guzmán-Fulgencio M, Berenguer J, Rallón N, Fernández-Rodríguez A, Miralles P, Soriano V, Jiménez-Sousa MA, Cosín J, Medrano J, García-Álvarez M, López JC, Benito JM, and Resino S
- Subjects
- Adult, Alleles, Coinfection, Female, Follow-Up Studies, Genotyping Techniques, HIV Infections genetics, Hepatitis C, Chronic genetics, Humans, Interferon alpha-2, Male, Middle Aged, Polymorphism, Single Nucleotide, Recombinant Proteins therapeutic use, Retrospective Studies, Viral Load, HLA-E Antigens, Antiviral Agents therapeutic use, HIV Infections drug therapy, Hepatitis C, Chronic drug therapy, Histocompatibility Antigens Class I genetics, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
Objectives: To analyze whether human leukocyte antigen (HLA)-E allelic variants are associated with and may predict response to peg-interferon (IFN) alpha and ribavirin treatment in HIV/hepatitis C virus (HCV)-coinfected patients., Design: Retrospective follow-up study., Methods: We studied 321 naive patients who started HCV treatment. HLA-E genotyping was performed by restriction fragment length polymorphism. A sustained virological response (SVR) was defined as undetectable plasma HCV-RNA up through 24 weeks after the end of HCV treatment., Results: The HLA-E*0101 allele increased the odds of achieving SVR for all patients [adjusted odds ratio (aOR) = 2.03 (95% confidence interval, 95% CI = 1.35-3.06); P = 0.001], for HCV genotype (GT) 1/4 patients (aOR = 1.62 (95% CI = 1.03-2.54), P = 0.035), and for GT2/3 patients [aOR = 9.87 (95% CI = 2.47-31.89), P = 0.001]. For decision tree analysis, the SVR rate increased from 0 to 82.6% and then to 92.5% in GT2/3 patients when the count of HLA-E*0101 alleles increased. In GT1/4 patients with rs8099917 TT genotype, the SVR rate increased from 33.3 to 54.8% and then to 61.8% when the count of HLA-E*0101 alleles increased. In GT1/4 patients with rs8099917 GT/GG genotype, the SVR rate increased from 15.4 to 22% and then to 44% when the count of HLA-E*0101 alleles increased. The overall percentage of patients correctly classified was 73.2% and the area under the receiver operating characteristic curve (AUROC) was 0.803 ± 0.024., Conclusion: The HLA-E*0101 allele was associated with increased odds of HCV clearance and could help to predict SVR among HIV/HCV-coinfected patients on HCV therapy. This would be helpful to avoid treatment in those less likely to respond to pegylated-interferon-alpha and ribavirin treatment.
- Published
- 2013
- Full Text
- View/download PDF
40. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
- Author
-
Fernández-Rodríguez A, Rallón N, Berenguer J, Jiménez-Sousa MA, Cosín J, Guzmán-Fulgencio M, Restrepo C, Lopez JC, García-Álvarez M, Miralles P, Soriano V, Benito JM, and Resino S
- Subjects
- Adult, Alleles, Coinfection, Drug Therapy, Combination, Female, Follow-Up Studies, HIV Infections complications, HIV Infections genetics, Hepacivirus pathogenicity, Hepatitis C, Chronic complications, Hepatitis C, Chronic genetics, Humans, Interferon alpha-2, Interferon-alpha therapeutic use, Interferons, Logistic Models, Male, Middle Aged, Polyethylene Glycols therapeutic use, Polymorphism, Single Nucleotide, Recombinant Proteins therapeutic use, Retrospective Studies, Ribavirin therapeutic use, Viral Load, Antiviral Agents therapeutic use, Cytokines blood, HIV Infections drug therapy, Hepatitis C, Chronic drug therapy, Interleukins genetics
- Abstract
Objectives: To estimate the impact of interleukin 28B (IL28B) polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) and their haplotypes on hepatitis C virus (HCV) treatment (peg-interferon-α and ribavirin) success in 324 HIV/HCV-coinfected patients. We also explore the behavior of plasma cytokine levels., Design: Retrospective follow-up study., Methods: Virologic response to HCV treatment was measured by plasma HCV viral load at different endpoints: rapid virologic response (RVR), early virologic response (EVR), end-of-treatment virologic response (ETVR) and sustained virologic response (SVR). IL28B polymorphisms were genotyped using GoldenGate assay. Finally, 13 cytokines were measured at baseline in 57 plasma samples using a multiplex immunoassay kit., Results: IL28B polymorphisms were strongly associated to virologic responses (RVR, EVR, ETVR, and SVR), although only for HCV genotypes 1 and 4 (P < 0.05). Strong linkage disequilibrium was detected for rs12980275/rs11881222 (r = 0.94) and rs8099917/rs7248668 (r = 0.99). IL28B haplotypes showed association but no improvement on treatment outcome prediction. Thus, the genotyping of only one single-nucleotide polymorphism was enough for predicting treatment response in GT1/4 patients with favorable rs12980275 (AA) genotype, while for subjects harboring unfavorable genotypes, the inclusion of rs8099917 was useful (SVR increased from 31 to 45%). Moreover, patients with rs12980275 (AA) that achieved SVR showed reduced plasma levels of Th1 (IFN-γ), Th2 (IL-6 and IL-9), and proinflammatory (TNF-α) cytokines., Conclusion: The presence of IL28B polymorphisms was significantly associated with HCV clearance during and after HCV therapy. The evaluated cytokine profile was much more favorable in patients with rs12980275 (AA) who achieved SVR.
- Published
- 2013
- Full Text
- View/download PDF
41. Genetic polymorphisms located in TGFB1, AGTR1, and VEGFA genes are associated to chronic renal allograft dysfunction.
- Author
-
Jiménez-Sousa MA, Fernández-Rodríguez A, Heredia M, Tamayo E, Guzmán-Fulgencio M, Lajo C, López E, Gómez-Herreras JI, Bustamante J, Bermejo-Martín JF, and Resino S
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Transplantation, Homologous, Graft Rejection genetics, Kidney Transplantation, Polymorphism, Single Nucleotide, Receptor, Angiotensin, Type 1 genetics, Transforming Growth Factor beta1 genetics, Vascular Endothelial Growth Factor A genetics
- Abstract
Background: Persistent inflammation and fibrosis have been related to active progression of renal deterioration and reduced survival of kidney transplant. The aim of this study was to determine the impact of single-nucleotide polymorphisms (SNPs) located in regions related to inflammatory and immune processes on the development of chronic renal allograft dysfunction (CRAD)., Methods: A retrospective study was carried out on 276 patients who received kidney transplant (KT). SNPs were genotyped via the SNPlex platform. Statistical analysis was performed with SNPstat and regression logistic analyses were adjusted by age and gender of recipients and donors, cold ischemia time and the number of human leukocyte antigen (HLA) mismatches., Results: From 276 patients with KT, 118 were non-CRAD and 158 were CRAD. Three SNPs showed significant associations with CRAD development: rs1800471 in transforming growth factor beta 1 (TGFB1), rs5186 in angiotensin II receptor type 1 (AGTR1), and rs699947 in vascular endothelial growth factor A (VEGFA). GC genotype of rs1800471 was associated with increased odds of CRAD compared to GG genotype (OR=2.65 (95% confidence interval (CI)=1.09; 6.47), p=0.025), as well as AC and AA genotype of rs699947 assuming a dominant model (OR=1.80 (95% CI=1.02; 3.20), p=0.044). Besides, AC and CC genotypes of rs5186 were associated with reduced odds of CRAD assuming a dominant model (OR=0.56 (95% CI=0.33; 0.96), p=0.033)., Conclusion: Our findings suggest that three genes related to immunity and inflammation (rs1800471, rs5186 and rs699947) are associated to susceptibility or protection to CRAD, and might have diagnostic utility in predicting the likelihood of developing CRAD., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
42. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
- Author
-
Guzmán-Fulgencio M, Jiménez JL, Berenguer J, Fernández-Rodríguez A, López JC, Cosín J, Miralles P, Micheloud D, Muñoz-Fernández MÁ, and Resino S
- Subjects
- Adult, Female, Follow-Up Studies, HIV Infections complications, Hepacivirus isolation & purification, Hepatitis C, Chronic complications, Hepatitis C, Chronic virology, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Treatment Failure, Viral Load, Antiviral Agents administration & dosage, HIV Infections drug therapy, Hepatitis C, Chronic drug therapy, Interferon-alpha administration & dosage, Interleukin-6 blood, Interleukin-9 blood, Ribavirin administration & dosage
- Abstract
Background: The cytokine profile plays an important role in treatment outcome of hepatitis C virus (HCV) infection, and probably modulates the immune response against HCV. The aim of this study was to evaluate which cytokines affect the response to interferon-α (IFN-α) and ribavirin therapy and how these cytokines change 72 weeks after starting anti-HCV therapy in HIV/HCV-coinfected patients., Methods: We carried out a retrospective follow-up study of 65 patients on anti-HCV therapy. A sustained virological response (SVR) was defined as an undetectable HCV viral load up to 24 weeks after the end of treatment. Cytokines were measured using a multiplex immunoassay kit., Results: On starting anti-HCV therapy, non-responder (NR) patients had higher levels of interleukin (IL)-6, IL-9, IL-10 and tumour necrosis factor (TNF)-α (P < 0.05), while IL-17A levels were increased in SVR patients (P = 0.058). However, only patients with high levels of IL-6 and IL-9 had decreased odds to achieve SVR (P < 0.05). Plasma levels of IL-6 and IL-9 had a high predictive value for SVR failure [area under the ROC curve (AUC) 0.839 (95% CI 0.733-0.945) and AUC 0.769 (95% CI 0.653-0.884)]. In addition, during anti-HCV therapy, IL-1β showed an increase in NR patients (P = 0.015) and IL-10 decreased in SVR patients (P = 0.049). After clearing HCV infection, low levels of TNF-α, IL-6, IL-9, IL-10, IL-13 and IL-22 were found in SVR patients (P < 0.05), as well as IL-1β, but only near statistical significance (P = 0.073)., Conclusions: High plasma levels of IL-6 and IL-9 had a high predictive value for SVR failure. Furthermore, clearing of HCV infection was associated with low inflammatory and T helper (Th)2/Th9/Th22 cytokine levels.
- Published
- 2012
- Full Text
- View/download PDF
43. European mitochondrial DNA haplogroups and metabolic disorders in HIV/HCV-coinfected patients on highly active antiretroviral therapy.
- Author
-
Micheloud D, Berenguer J, Guzmán-Fulgencio M, Campos Y, García-Álvarez M, Catalán P, Cosín J, Miralles P, López JC, and Resino S
- Subjects
- Adiponectin blood, Adult, Antiretroviral Therapy, Highly Active, Atherosclerosis genetics, Atherosclerosis metabolism, Atherosclerosis virology, Base Sequence, Blood Glucose metabolism, Cross-Sectional Studies, Dyslipidemias genetics, Dyslipidemias metabolism, Dyslipidemias virology, Europe epidemiology, Female, Hepatocyte Growth Factor blood, Humans, Insulin blood, Insulin Resistance genetics, Male, Middle Aged, Molecular Sequence Data, Nerve Growth Factor blood, White People genetics, Coinfection drug therapy, Coinfection virology, DNA, Mitochondrial genetics, HIV Infections drug therapy, Haplotypes, Hepatitis C, Chronic drug therapy
- Abstract
Background: Mitochondrial DNA (mtDNA) haplogroups play an important role in susceptibility to metabolic disorders and cardiovascular disease., Methods: We carried out a cross-sectional study in 248 HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy to investigate whether mtDNA haplogroups had any influence on metabolic disorders. mtDNA genotyping was performed using the Sequenom MassARRAY platform. Insulin resistance (IR) was estimated using the homeostatic model assessment (HOMA) (HOMA ≥ 3.8), which was calculated as fasting plasma glucose (mmol/L) times fasting serum insulin (mU/L) divided by 22.5. A high atherogenic risk was assessed when the atherogenic index (AI) was ≥3.5. AI was calculated as total cholesterol (mg/dL) divided by HDL (mg/dL)., Results: The major haplogroup HV and haplogroup H had reduced odds ratios of IR (HOMA ≥ 3.8) [0.45 (95% CI: 0.24 to 0.85) and 0.36 (95% CI: 0.18 to 0.69), respectively], and high AI (AI ≥ 3.5) [0.44 (95% CI: 0.22 to 0.87) and 0.40 (95% CI: 0.19 to 0.80), respectively]. The major haplogroup U had increased odds of IR [2.66 (95% CI: 1.39 to 5.8)]. The major haplogroup JT and haplogroup T had increased odds of high AI [2.86 (95% CI: 1.29 to 6.33) and 4.01 (95%CI: 1.59 to 10.03), respectively]. Additionally, we found that patients belonging to the major haplogroup HV had lower values of serum hepatic growth factor and nerve growth factor, and higher values of adiponectin than patients belonging to the major haplogroup JT (P < 0.05)., Conclusions: mtDNA haplogroups were associated with IR and atherogenic dyslipidemia; suggesting that mitochondrial genomics may play a significant role in metabolic disorders and cardiovascular diseases in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy.
- Published
- 2011
- Full Text
- View/download PDF
44. Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy.
- Author
-
Guzmán-Fulgencio M, Medrano J, Rallón N, Echeverria-Urabayen A, Miguel Benito J, Restrepo C, García-Álvarez M, Vispo E, San Roman J, Sánchez-Piedra C, Soriano V, and Resino S
- Subjects
- Adult, Cardiovascular Diseases physiopathology, Case-Control Studies, Cross-Sectional Studies, Endothelium, Vascular metabolism, Endothelium, Vascular physiopathology, Female, HIV Infections complications, HIV Infections physiopathology, Humans, Inflammation, Male, Middle Aged, Risk Assessment methods, Risk Factors, Spain, Antiretroviral Therapy, Highly Active adverse effects, Biomarkers blood, Cardiovascular Diseases chemically induced, Endothelium, Vascular drug effects, HIV Infections drug therapy
- Abstract
Objective: To evaluate the association between biomarkers of inflammation and endothelial dysfunction and Framingham scores (FS) for risk of coronary heart disease (FS-CHD), stroke (FS-Stroke) or any cardiovascular event (FS-CVE) in HIV-infected on suppressive highly active antiretroviral therapy (HAART)., Methods: A cross-sectional study was conducted in 73 HIV-infected patients and 23 healthy controls. Inflammatory molecules and endothelial dysfunction markers were measured using a multiplex immunoassay (plasminogen activator inhibitor type 1 (PAI-1), soluble TNF receptor type 1 (sTNF-R1), soluble CD40 ligand (sCD40L), soluble E-selectin (sE-selectin), soluble P-selectin (sP-selectin), soluble intercellular adhesion molecules (sICAM-1) and soluble vascular cell adhesion molecule (sVCAM-1). Outcome variables were FS-CHD ≥10%, FS-Stroke ≥5% and FS-CVE ≥10%., Results: Significant differences (p < 0.05) were found comparing controls and HIV patients for PAI-1 (5.4 vs. 13.5 ng/dL), sTNF-R1 (0.85 vs. 1.09 ng/dL), sICAM-1 (529 vs. 858 ng/dL), sE-selectin (73.7 vs. 120 ng/dL), sP-selectin (676 vs. 1511 ng/dL) sCD40L (76 vs. 307 ng/dL), FS-CHD (4% vs. 7.8% L), FS-Stroke (2% vs. 2.8%) and FS-CVE (5% vs. 11%). In HIV-infected patients, the adjusted logistic regression analysis revealed that sTNF-R1 levels were significantly associated with increased FS-CHD>10% (OR: 11.51 (95% CI: 1.14; 115.84); p = 0.038) and FS-CVE (OR: 12.41 (95% CI: 1.25; 123.23); p = 0.031)., Conclusions: HIV-infected patients show higher levels of soluble inflammatory and endothelial dysfunction markers than controls and have a two-fold increased FS of presenting coronary heart disease, stroke or cardiovascular events at 10 years. Furthermore, sTNF-R1 displayed the best association with FS of coronary heart disease and any cardiovascular event in our patients., (Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
45. European mitochondrial DNA haplogroups and liver fibrosis in HIV and hepatitis C virus coinfected patients.
- Author
-
García-Álvarez M, Guzmán-Fulgencio M, Berenguer J, Micheloud D, Campos Y, López JC, Cosín J, Miralles P, Alvarez E, and Resino S
- Subjects
- Adult, Case-Control Studies, Cross-Sectional Studies, Disease Progression, Female, Humans, Liver Cirrhosis complications, Male, Polymorphism, Genetic, Spain, White People, DNA, Mitochondrial genetics, HIV Infections complications, Haplotypes, Hepatitis C complications, Liver Cirrhosis genetics
- Abstract
Background: HIV infection, hepatitis C virus (HCV) liver disease, and mitochondrial DNA (mtDNA) polymorphisms are three possibly interrelated factors that might be associated with progression of liver disease. The aim of this study was to investigate whether mtDNA haplogroups had any influence on liver fibrosis progression in HIV/HCV coinfected patients., Methods: We carried out a cross-sectional study in 231 patients who were genotyped via Sequenom's MassARRAY platform (San Diego, California, USA). Liver fibrosis was estimated based on the METAVIR score. In each patient, fibrosis progression rate (FPR) was calculated by dividing the fibrosis stage (0-4) by the estimated duration of HCV infection in years., Results: The cluster or major haplogroup HV was significantly associated with reduced odds ratios (OR) for advanced fibrosis [OR 0.35, 95% confidence interval (CI) 0.16-0.77, P = 0.009], cirrhosis (OR 0.16, 95% CI 0.04-0.60, P = 0.007), or high FPR (OR 0.43, 95% CI 0.21-0.84, P = 0.015). Within the major haplogroup HV, haplogroup H was significantly associated with an absence of advanced fibrosis (OR 0.40, 95% CI 0.18-0.91, P = 0.029), cirrhosis (OR 0.14, 95% CI 0.03-0.67, P = 0.014), or high FPR (OR 0.47, 95% CI 0.23-0.95, P = 0.035). We also found a significant association with increased odds of cirrhosis (OR 5.25, 95% CI 1.76-15.64, P = 0.003) in the closely related major haplogroup U., Conclusion: The mtDNA haplogroups HV and H were associated with slower fibrosis progression, and the haplogroup U was associated with faster fibrosis progression in HIV/HCV coinfected patients. These data suggest that mtDNA haplogroup may play a significant role in liver fibrogenesis during HCV infection.
- Published
- 2011
- Full Text
- View/download PDF
46. High plasma fractalkine (CX3CL1) levels are associated with severe liver disease in HIV/HCV co-infected patients with HCV genotype 1.
- Author
-
García-Álvarez M, Berenguer J, Guzmán-Fulgencio M, Micheloud D, Catalán P, Muñoz-Fernandez MÁ, Alvarez E, and Resino S
- Subjects
- Adult, Biopsy, Cross-Sectional Studies, Female, Fibrosis pathology, Genotype, HIV Infections virology, Hepatitis C virology, Humans, Inflammation, Liver Diseases complications, Male, Middle Aged, Odds Ratio, Chemokine CX3CL1 biosynthesis, HIV Infections metabolism, Hepacivirus genetics, Hepatitis C metabolism, Liver Diseases virology
- Abstract
Background: Inappropriate persistence of chemokines expression in hepatitis C virus (HCV) infection can drive tissue damage, intrahepatic inflammation, and liver cell injury. The aim of study was to study the association of plasma fractalkine (CX3CL1) levels with fibrosis stage and necroinflammatory activity grade of liver biopsies in human immunodeficiency virus (HIV)/HCV co-infected patients with HCV genotype 1., Methods: We carried out a cross-sectional study on 125 patients. Grading and staging of liver biopsies were carried out by METAVIR score. Plasma CX3CL1 was measured using an immunoassay kit., Results: Patients with advanced fibrosis had higher CX3CL1 levels than those with mild or no fibrosis (p=0.010); and patients with severe activity grade had higher CX3CL1 levels than those with low activity grade (p=0.040). Plasma CX3CL1 levels were significantly associated with increased odds of significant fibrosis (odds ratio (OR): 3.47 (95% of confidence interval (95%CI): 1.04; 11.58)), advanced fibrosis (OR: 6.78 (95%CI: 1.70; 26.93)), and moderate necroinflammatory activity grade (OR: 4.09 (95%CI: 1.21; 13.87)). When we analyzed fibrosis stages and activity grades of METAVIR score together, we found a positive significant association of CX3CL1 levels with moderate activity grade/significant fibrosis (OR: 5.49 (95%CI: 1.46; 20.58)) and moderate activity grade/advanced fibrosis (OR: 8.99 (95%CI: 2.06; 39.23))., Conclusion: Plasma CX3CL1 levels were independently associated with several characteristics of severe liver disease in HIV/HCV coinfected patients with HCV-genotype 1, suggesting a role of CX3CL1 in the pathogenesis of HCV infection., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
47. Cardiovascular risk markers are increased in HIV-infected children with lipodystrophy syndrome.
- Author
-
Guzmán-Fulgencio M, Micheloud D, Lorente R, Bellón JM, Gomez MI, Gurbindo MD, León JA, Muñoz-Fernández MÁ, and Resino S
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Male, Risk Assessment, Anti-HIV Agents adverse effects, Antiretroviral Therapy, Highly Active methods, Biomarkers blood, Cardiovascular Diseases diagnosis, HIV-Associated Lipodystrophy Syndrome chemically induced, HIV-Associated Lipodystrophy Syndrome complications
- Published
- 2011
- Full Text
- View/download PDF
48. Sustained virological response to interferon-α plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients.
- Author
-
Guzmán-Fulgencio M, Berenguer J, de Castro IF, Micheloud D, López JC, Cosín J, Miralles P, Lorente R, Aldamiz-Echevarría T, Muñoz-Fernández MÁ, and Resino S
- Subjects
- Adult, Biomarkers blood, E-Selectin blood, Endothelial Cells physiology, Female, HIV Infections drug therapy, Hepatitis C drug therapy, Humans, Intercellular Adhesion Molecule-1 blood, Male, Middle Aged, P-Selectin blood, Receptors, Tumor Necrosis Factor, Type I blood, Retrospective Studies, Treatment Outcome, Viral Load, Antiviral Agents administration & dosage, HIV Infections complications, HIV Infections pathology, Hepatitis C complications, Hepatitis C pathology, Interferon-alpha administration & dosage, Ribavirin administration & dosage
- Abstract
Objectives: Hepatitis C virus (HCV) antiviral therapy might lead to decreased chronic immune activation and endothelial dysfunction associated with cardiovascular risk. The aim was to evaluate the effect of HCV eradication on serum markers of inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients., Methods: We carried out a retrospective study of 69 HIV/HCV co-infected patients on interferon (IFN)-α plus ribavirin. In addition, 47 HIV-infected subjects were selected as a control group. A sustained virological response (SVR) was defined as an undetectable HCV viral load up to 24 weeks after the end of treatment. Tumour necrosis factor (TNF) receptor-1 (TNF-R1), soluble E-selectin (sE-selectin), soluble P-selectin (sP-selectin), soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1) were measured using a multiplex immunoassay kit., Results: HIV/HCV co-infected patients had higher values of soluble TNF-R1 (sTNF-R1), sE-selectin and sICAM-1 than HIV mono-infected patients (P < 0.05). SVR patients had a decrease in sTNF-R1, sP-selectin, sE-selectin and sICAM-1 during anti-HCV treatment (P < 0.05) and, at the end of treatment, SVR patients had lower values of sTNF-R1, sE-selectin and sVCAM-1 than non-responder patients (P < 0.05), although the values of sTNF-R1, sP-selectin, sE-selectin and sICAM-1 remained higher than in HIV mono-infected patients (P < 0.05). Moreover, we found a significant positive relationship between an increase in sTNF-R1 and increases in sP-selectin, sE-selectin and sICAM-1 during anti-HCV therapy., Conclusions: Chronic hepatitis C infection induces alterations of markers of inflammation and endothelial dysfunction. Eradication of HCV, following IFN-α and ribavirin therapy, reduces immune activation as well as markers of inflammation and endothelial dysfunction.
- Published
- 2011
- Full Text
- View/download PDF
49. Sustained virologic response decreases serum markers of angiogenesis, inflammation, and fibrosis in HIV/HCV-coinfected patients on hepatitis C virus therapy.
- Author
-
García-Álvarez M, Berenguer J, Micheloud D, Guzmán-Fulgencio M, Catalán P, López JC, Cosín J, Miralles P, Carrero-Gras A, and Resino S
- Subjects
- Adult, Antiviral Agents administration & dosage, Biomarkers, Drug Therapy, Combination, Female, Hepatitis C virology, Humans, Inflammation metabolism, Interferon-alpha administration & dosage, Liver Cirrhosis metabolism, Male, Middle Aged, Neovascularization, Pathologic metabolism, Retrospective Studies, Ribavirin administration & dosage, Antiviral Agents therapeutic use, HIV Infections complications, Hepatitis C complications, Interferon-alpha therapeutic use, Ribavirin therapeutic use
- Published
- 2011
- Full Text
- View/download PDF
50. Serum levels of adipokines in HIV/HCV co-infected patients and their association with insulin resistance and liver disease severity.
- Author
-
de Castro IF, Berenguer J, Micheloud D, Guzmán-Fulgencio M, Cosín J, Alvarez E, López JC, Miralles P, García-Álvarez M, and Resino S
- Subjects
- Adult, Female, Humans, Male, Serum chemistry, Severity of Illness Index, Adipokines blood, HIV Infections complications, HIV Infections pathology, Hepatitis C complications, Hepatitis C pathology, Insulin Resistance, Liver Cirrhosis pathology
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.